Dual Targeting of FGFR4 and PI3K–mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma
Dual pathway inhibition consistently and additively suppressed tumor-associated phenotypes despite compensatory MAPK activation, with the clearest added benefit over fisogatinib alone in migration, cell-cycle control, and 4E-BP1 modulation, supporting translational regulation as a shared therapeutic vulnerability.